Meds A-Z

Melarsomine Dihydrochloride

Detailed information about Melarsomine Dihydrochloride

Official label facts Owner quick guide first Marketing clearly labeled

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For the treatment of stabilized Class 1, 2, and 3 heartworm disease caused by immature (4 month-old, stage L5) to mature adult infections of Dirofilaria immitis .

What it does:

When it's needed:

Call your vet sooner if you notice:

Administer only by deep intramuscular injection in the lumbar muscles (L3 - L4). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Not for use in breeding animals and lactating or pregnant bitches. IMMITICIDE® should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in breeding animals and lactating or pregnant bitches. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Administer only by deep intramuscular injection in the lumbar muscles (L3 – L5). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. DIROBANTM should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Commonly reported reactions:

(1 reports)
(1 reports)
(1 reports)

What to ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Talk to a Vet / Find a Vet Near You

Image coming soon

Melarsomine Dihydrochloride

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: MSK

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: MSK

Form: Liquid (Solution), Powder

Identifiers:

ANADA: 200609 NADA: 141042 NDC Package: 54771-1920-1 NDC Product: 54771

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200609 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141042 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Administer only by deep intramuscular injection in the lumbar muscles (L3 - L4). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Not for use in breeding animals and lactating or pregnant bitches. IMMITICIDE® should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in breeding animals and lactating or pregnant bitches. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Administer only by deep intramuscular injection in the lumbar muscles (L3 – L5). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. DIROBANTM should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

High: Administer only by deep intramuscular injection in the lumbar muscles (L3 - L4). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Not for use in breeding animals and lactating or pregnant bitches. IMMITICIDE® should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in breeding animals and lactating or pregnant bitches. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Administer only by deep intramuscular injection in the lumbar muscles (L3 – L5). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. DIROBANTM should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Most Reported Reactions

Cases	Species	Serious cases
1	Dog	1
1	Cat	1
1	Dog	1
1	Dog	1
1	Dog	1
1	Dog	1
1	Dog	1
1	Dog	1

Species coverage: Dog (25) Cat (7)

View detailed reaction table

Species	Seriousness	Frequency	Reports
Dog	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Cat	Unknown	-	-
Cat	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-056096

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 3 • Secondary summaries: 0

Official label facts

FOI Summary oA 200-609 Approved February 17, 2017.pdf · FOI
DIROBAN® · SPL
Immiticide Sterile Powder · SPL

Secondary summaries

No source yet.

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/201 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2593/DIROBAN%C2%AE · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1211/Immiticide%20Sterile%20Powder · document · SPL

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.

Talk to a Vet / Find a Vet Near You

Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: DIROBAN® Immiticide Sterile Powder

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Dog

Rx/OTC: RX

Form/route: Liquid (Solution), Powder • Intramuscular

Applications: ANADA 200-609 • NADA 141-042

Documents: 1 (FOI: 1) • SPL: 2 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 56 • Cat 5 • View

Case summaries: 7 (showing 7) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Heartworm Disease

Linked using: Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: B74.8

Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Administer only by deep intramuscular injection in the lumbar muscles (L3 - L4). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Not for use in breeding animals and lactating or pregnant bitches. IMMITICIDE® should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in breeding animals and lactating or pregnant bitches. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Administer only by deep intramuscular injection in the lumbar muscles (L3 – L5). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. DIROBANTM should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)

Top reaction signals

Abnormal cytology (1) Blood in faeces (1) Cardiorespiratory arrest (1) Corneal ulcer (1) Death (1) Diarrhoea (1) Dyspnoea (1) Groaning (1) Haemorrhagic gastroenteritis (1) Heavy breathing (1) Hypersalivation (1) Inappetence (1) Injection site lump (1) Injection site pain (1) Lack of efficacy (endoparasite) - heartworm (1) Lethargy (see also Central nervous system depression in Neurological) (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

ANADA: 200609 NADA: 141042 NDC Package: 54771-1920-1 NDC Product: 54771

Package NDC	Product NDC	Form / Route	Status
54771-1920-1	54771		-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

FOI Summary oA 200-609 Approved February 17, 2017.pdf • FOI summary • Official • Jan. 28, 2020
FDA FOI summary for application 200609

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 4 Clinical 0 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: Administer only by deep intramuscular injection in the lumbar muscles (L3 - L4). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 p… (Official, 2026-02-12)
side_effects: Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Injection site swelling, INEFFECTIVE, HEARTWORM ADULTS, Lethargy (see … (Official, 2026-02-12)
usage: Treatment of stabilized, class 1, 2, and 3 heartworm disease (asymptomatic to mild, moderate, and severe, respectively) caused by immature (4 month-old, stage … (Official, 2026-02-12)

Recent Revisions

side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
DIROBAN® RX Melarsomine Dihydrochloride Powder • Intramuscular Label highlights Official documents	Anzac Animal Health, LLC	ANADA 200-609	Approved	Jan 28, 2020
Immiticide Sterile Powder RX Melarsomine Dihydrochloride Liquid (Solution) • Intramuscular Label highlights Official documents	Boehringer lngelheim Animal Health USA, Inc.	NADA 141-042	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Contains 50.0 mg melarsomine dihydrochloride and 33.75 mg glycine USP. 1 vial: when reconstituted with 2 mL of sterile water for injection (provided) contains 25 mg/mL of active ingredient.

Dogs

Indication

For the treatment of stabilized Class 1, 2, and 3 heartworm disease caused by immature (4 month-old, stage L5) to mature adult infections of Dirofilaria immitis.

Dosage

For severe (class 3) heartworm disease: administer a single injection of 2.5 mg/kg then approximately 1 month later with 2.5 mg/kg administered twice 24 hours apart.

For asymptomatic to moderate (class 1 to 2) heartworm disease: administer 2.5 mg/kg intramuscularly in the lumbar (L3 - L5) muscles twice, 24 hours apart. Four months following treatment, a second treatment series (2.5 mg/kg twice, 24 hours apart) can be elected taking into consideration the response to the first treatment and the condition, age, and use of the dog.

Limitations

Not for use in breeding animals and lactating or pregnant bitches. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Administer only by deep intramuscular injection in the lumbar muscles (L3 – L5). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use in alternate sides with each administration. DIROBANTM should be administered by deep intramuscular injection in the lumbar (epaxial) muscles (L3 - L5) ONLY. DO NOT USE IN ANY OTHER MUSCLE GROUP. DO NOT USE INTRAVENOUSLY. Care should be taken to avoid superficial injection or leakage. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Not Breeding Animals

Composition / specifications

Contains 50.0 mg melarsomine dihydrochloride and 33.75 mg glycine USP.
1 vial: when reconstituted with 2 mL of sterile water for injection (provided) contains 25 mg/mL of active ingredient.

Dogs (Class 3 Heartworm Disease)

Indication

Dosage

For severe (class 3) heartworm disease: Single injection of 2.5 milligrams per kilogram followed approximately 1 month later, by 2.5 milligrams per kilogram administered twice, 24 hours apart.

Limitations

Dogs (Class 1 and 2 Heartworm Disease)

Indication

Dosage

For asymptomatic to moderate (class 1 to class 2) heartworm disease: 2.5 milligrams per kilogram of body weight (1.1 milligram per pound) twice, 24 hours apart. The series can be repeated in 4 months depending on the response to the first treatment and the condition, age, and use of the dog.

Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents

FOI FOI Summary oA 200-609 Approved February 17, 2017.pdf

Summary

DIROBAN Sterile Powder for Injection is indicated for the treatment of stabilized Class 1, 2, and 3 heartworm disease caused by immature (4 month-old, stage L5) to mature adult infections of Dirofilaria immitis.

SPL Packages

DIROBAN® (ZIP)

FDA page: Open in Animal Drugs @ FDA

SPL Packages

Immiticide Sterile Powder (ZIP)

FDA page: Open in Animal Drugs @ FDA

Usage

Treatment of stabilized, class 1, 2, and 3 heartworm disease (asymptomatic to mild, moderate, and severe, respectively) caused by immature (4 month-old, stage L5) to mature adult infections of Dirofilaria immitis in dogs. For the treatment of stabilized Class 1, 2, and 3 heartworm disease caused by immature (4 month-old, stage L5) to mature adult infections of Dirofilaria immitis .

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 56 and Cat 5 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog

Digestive

Vomiting (828) Diarrhea (417) Vomiting (8) Vomiting (8) Vomiting (8) Vomiting (8) Diarrhea (7) Diarrhea (7) Diarrhea (7) Diarrhea (7) Diarrhea (7) Vomiting (7) Diarrhea (6) Vomiting (5)

Skin & allergy

Injection site swelling (685) Injection site swelling (7) Injection site swelling (7) Injection site swelling (7) Injection site swelling (7) Injection site swelling (7) Injection site swelling (7)

Neurologic

Tiredness (lethargy) (515) Tiredness (lethargy) (9) Tiredness (lethargy) (9) Tiredness (lethargy) (9) Tiredness (lethargy) (9) Tiredness (lethargy) (8) Tiredness (lethargy) (7)

Effectiveness

Lack of efficacy (endoparasite) - heartworm (2228) Lack of efficacy (endoparasite) - heartworm (16) Lack of efficacy (endoparasite) - heartworm (16) Lack of efficacy (endoparasite) - heartworm (16) Lack of efficacy (endoparasite) - heartworm (16) Lack of efficacy (endoparasite) - heartworm (15) Lack of efficacy (endoparasite) - heartworm (15)

Other

INEFFECTIVE, HEARTWORM ADULTS (541) Injection site lump (495) Injection site pain (427) Medication error NOS (8) Medication error NOS (8) Medication error NOS (8) Medication error NOS (8) Medication error NOS (7) Medication error NOS (7) Abnormal radiograph finding (5) Abnormal radiograph finding (5) Abnormal radiograph finding (5) Abnormal radiograph finding (5) Abnormal radiograph finding (5) Injection site lump (5) Injection site lump (5) Injection site lump (5) Injection site lump (5) Pain NOS (5) Abnormal radiograph finding (4) Injection site lump (4)

Cat

Skin & allergy

Twitching (1)

Other

Cardiorespiratory arrest (1) Death (1) Heavy breathing (1) Trouble breathing (dyspnea) (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Rottweiler, Female, 6 year, 55.338 kilogram • Drug: MSK, Powder, Intramuscular, Dose: 5.60 mL per animal • Reactions: Corneal ulcer • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-056099
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 6.00 Year
Weight: 55.338 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Powder
Dose: 5.60 mL per animal

Reactions Reported:

Corneal ulcer

Outcomes: Ongoing

Dog, Crossbred Canine/dog, Male, 4 year, 33.112 kilogram • Drug: MSK, Powder, Intramuscular, Frequency: 1 per day • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-056101
Serious AE: Yes
Treated For AE: No
Sex: Male
Age: 4.00 Year
Weight: 33.112 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Powder
Frequency: 1 per day

Reactions Reported:

Lack of efficacy (endoparasite) - heartworm

Outcomes: Ongoing

Dog, Crossbred Canine/dog, Female, 8 year, 33.112 kilogram • Drug: MSK, Powder, Intramuscular • Reactions: Diarrhea, Blood in faeces, Vomiting, Inappetence, Haemorrhagic gastroenteritis • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-056097
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 8.00 Year
Weight: 33.112 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Powder

Reactions Reported:

Diarrhea Blood in faeces Vomiting Inappetence Haemorrhagic gastroenteritis

Outcomes: Recovered/Normal

Dog, Shepherd Dog - German, Female, 3 year, 39.463 kilogram • Drug: MSK, Powder, Intramuscular, Dose: 3.90 mL per animal • Reactions: Tiredness (lethargy), Drooling, Restlessness, Groaning • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-054508
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 3.00 Year
Weight: 39.463 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Powder
Dose: 3.90 mL per animal

Reactions Reported:

Tiredness (lethargy) Drooling Restlessness Groaning

Outcomes: Ongoing

Dog, Rottweiler, Female, 3 year, 36.741 kilogram • Drug: MSK, Powder, Intramuscular, Dose: 3.80 mL per animal • Reactions: Injection site lump, Abnormal cytology, Injection site pain • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-056096
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 3.00 Year
Weight: 36.741 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Powder
Dose: 3.80 mL per animal

Reactions Reported:

Injection site lump Abnormal cytology Injection site pain

Outcomes: Ongoing

Cat, Cat (other), Female, 8 month, 2.903 kilogram • Drug: MSK, Powder, Intramuscular, Dose: 1.60 mL per animal • Reactions: Heavy breathing, Twitching • Outcome: Ongoing

Report ID: USA-USFDACVM-2021-US-047309
Serious AE: Yes
Treated For AE: No
Sex: Female
Age: 8.00 Month
Weight: 2.903 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Powder
Dose: 1.60 mL per animal

Reactions Reported:

Heavy breathing Twitching

Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 3 year, 3.402 kilogram • Drug: MSK, Suspension, Dose: 12 Milligram per unknown • Reactions: Trouble breathing (dyspnea), Cardiorespiratory arrest, Death • Outcome: Died

Report ID: USA-USFDACVM-2016-US-041192
Serious AE: Yes
Treated For AE: No
Sex: Female
Age: 3.00 Year
Weight: 3.402 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension
Dose: 12 Milligram per unknown

Reactions Reported:

Trouble breathing (dyspnea) Cardiorespiratory arrest Death

Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on PetWisePlus are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Melarsomine Dihydrochloride

Pet Owner Quick Guide